NILOTINIB 400 MG BID DAILY AS FRONTLINE THERAPY OF PH plus CHRONIC MYELOID LEUKEMIA: DOSE DELIVERY AND SAFETY PROFILE AT 2 YEARS

被引：0

作者：

Castagnetti, F. ^{[1
]}

Palandri, F. ^{[1
]}

Breccia, M. ^{[2
]}

Levato, L. ^{[3
]}

Capucci, A. ^{[4
]}

Tiribelli, M. ^{[5
]}

Zaccaria, A. ^{[6
]}

Bocchia, M. ^{[7
]}

Cuneo, A. ^{[8
]}

Stagno, F. ^{[9
]}

Specchia, G. ^{[10
]}

Musso, M. ^{[11
]}

Gugliotta, G. ^{[1
]}

Testoni, N. ^{[1
]}

Alimena, G. ^{[2
]}

Pane, F. ^{[12
]}

Martinelli, G. ^{[1
]}

Saglio, G. ^{[13
]}

Baccarani, M. ^{[1
]}

Rosti, G. ^{[1
]}

机构：

[1] Univ Bologna, Dpt Hematol & Oncol Seragnoli, Bologna, Italy

[2] Univ Roma La Sapienza, Dept Biotechnol & Hematol, Rome, Italy

[3] A Pugliese Hosp, Hematol Unit, Catanzaro, Italy

[4] Spedali Civil Brescia, Hematol Unit, I-25125 Brescia, Italy

[5] Univ Udine, Dept Med & Morphol Res, I-33100 Udine, Italy

[6] Ravenna Hosp, Hematol Unit, Ravena, Italy

[7] Univ Siena, Dept Hematol, I-53100 Siena, Italy

[8] Univ Ferrara, Dept Hematol, I-44100 Ferrara, Italy

[9] Univ Catania, Dept Biomed Sci, Catania, Italy

[10] Univ Bari, Dept Hematol, Bari, Italy

[11] La Madalena Hosp, Hematol & Bone Marrow Transplantat Unit, Palermo, Italy

[12] Univ Naples Federico II, Dept Biochem & Med Biotechnol, Naples, Italy

[13] Univ Turin, Dpt Clin & Biol Sci, Orbassano, Italy

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0814

引用

页码：340 / 341

页数：2

共 50 条

[31] Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia
Gener-Ricos, Georgina
Haddad, Fadi
Sasaki, Koji
Issa, Ghayas C.
Skinner, Jeffrey
Takahashi, Koichi
Masarova, Lucia
Burger, Jan A.
Borthakur, Gautam
Bose, Prithviraj
Garcia-Manero, Guillermo
Jabbour, Elias
Kantarjian, Hagop
BLOOD, 2022, 140 : 1493 - 1494
[32] Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results
Gener-Ricos, Georgina
Haddad, Fadi G.
Sasaki, Koji
Issa, Ghayas C.
Skinner, Jeffrey
Masarova, Lucia
Borthakur, Gautam
Alvarado, Yesid
Garcia-Manero, Guillermo
Jabbour, Elias
Kantarjian, Hagop
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (10): : 742 - 748
[33] Clinical Significance of Dose Reductions of Dasatanib and Nilotinib When Used As Frontline Therapy for Chronic Phase -Chronic Myeloid Leukemia (CML-CP) Does Not Affect Outcome
Malik, Asifa
Kantarjian, Hagop M.
Quintas-Cardama, Alfonso
O'Brien, Susan
Verstovsek, Srdan
Borthakur, Gautam
Ravandi, Farhad
Thomas, Deborah A.
Burton, Elizabeth M.
Jabbour, Elias
Cortes, Jorge E.
BLOOD, 2011, 118 (21) : 1617 - 1618
[34] A Multi-centric Bioequivalence Trial in Ph plus Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets
Arora, Rachna
Sharma, Manju
Monif, Tausif
Iyer, Sunil
CANCER RESEARCH AND TREATMENT, 2016, 48 (03): : 1120 - 1129
[35] Efficacy of Frontline Nilotinib Therapy in Patients. (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP)
Quintas-Cardama, Alfonso
Kantarjian, Hagop M.
Luthra, Rajyalakshmi
O'Brien, Susan
Jabbour, Elias
Borthakur, Gautam
Ravandi, Farhad
Garcia-Manero, Guillermo
Faderl, Stefan
Konopleva, Marina
Wierda, William G.
Burton, Elizabeth
Cortes, Jorge E.
BLOOD, 2011, 118 (21) : 210 - 210
[36] Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph plus chronic myeloid leukemia patients
Piazza, RG
Magistroni, V
Andreoni, F
Franceschino, A
Tornaghi, L
Varella-Garcia, M
Bungaro, S
Colnaghi, F
Corneo, G
Pogliani, EM
Gambacorti-Passerini, C
LEUKEMIA, 2005, 19 (11) : 1985 - 1987
[37] Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up
Saydam, Guray
Haznedaroglu, Ibrahim Celalettin
Kaynar, Leylagul
Yavuz, Akif S.
Ali, Ridvan
Guvenc, Birol
Akay, Olga M.
Baslar, Zafer
Ozbek, Ugur
Sonmez, Mehmet
Aydin, Demet
Pehlivan, Mustafa
Undar, Bulent
Dagdas, Simten
Ayyildiz, Orhan
Akin, Gulnur
Dag, Ilkiz M.
Ilhan, Osman
HEMATOLOGY, 2018, 23 (10) : 771 - 777
[38] Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis
Jabbour, Elias
Sasaki, Koji
Haddad, Fadi G.
Issa, Ghayas C.
Skinner, Jeffrey
Dellasala, Sara
Yilmaz, Musa
Ferrajoli, Alessandra
Bose, Prithviraj
Thompson, Philip
Alvarado, Yesid
Jain, Nitin
Garcia-Manero, Guillermo
Takahashi, Koichi
Borthakur, Gautam
Pemmaraju, Naveen
Pierce, Sherry
Kantarjian, Hagop
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (11) : 1413 - 1418
[39] Low-Dose Dasatinib 50 Mg/Day Versus Standard-Dose Dasatinib 100 Mg/Day As Frontline Therapy in Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis
Sasaki, Koji
Jabbour, Elias J.
Issa, Ghayas C.
Naqvi, Kiran
Skinner, Jeffrey
Anderson, Kristin
Dellasala, Sara E.
Yilmaz, Musa
Ferrajoli, Alessandra
Bose, Prithviraj
Thompson, Philip A.
Alvarado, Yesid
Jain, Nitin
Garcia-Manero, Guillermo
Takahashi, Koichi
Burger, Jan A.
Borthakur, Gautam
Pemmaraju, Naveen
Haddad, Fadi
Khouri, Maria R.
Paul, Shilpa
Pierce, Sherry A.
Cortes, Jorge E.
Kantarjian, Hagop
BLOOD, 2021, 138
[40] Analysis of the GeneXpert System on the International Multicentre ICORG 08-02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML)
O'Dwyer, Michael E.
Swords, Ronan
Giles, Francis
McMullin, Mary Frances
le Coutre, Philipp D.
Nagler, Arnon
Langabeer, Stephen
Wieczorkowska, Marzena
McDowell, Cliona
Egan, Karine
Moulton, Brian
Conneally, Eibhlin
BLOOD, 2011, 118 (21) : 1612 - 1613

← 1 2 3 4 5 →